Previous 10 | Next 10 |
-- Previously disclosed data demonstrated statistically significant and clinically meaningful reductions in weight and hunger in patients with Bardet-Biedl syndrome -- BOSTON, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharma...
-- U.S. launch of IMCIVREE ® (setmelanotide) for Bardet-Biedl Syndrome progresses with strong demand with more than 120 prescriptions since FDA approval -- -- EC authorization for IMCIVREE expanded to include BBS; UK launch in POMC and LEPR deficiencies und...
-- Analyses of Clinical Registry Investigating Bardet-Biedl Syndrome (CRIBBS) in children with BBS showed a significant positive correlation between degree of hyperphagia and body mass index (BMI) -- -- 84% of patients with BBS in Phase 3 clinical trial showed clinical benefit o...
-- Phase 3 clinical trial design reflects feedback obtained during recent discussions with FDA -- -- 89 percent (16 of 18) patients achieved primary endpoint with a BMI decrease greater than 5 percent at 16 weeks on setmelanotide therapy ( P<0.0001) – -- Long...
Commercial-stage biotech Rhythm Pharmaceuticals ( NASDAQ: RYTM ) added ~5% pre-market Tuesday after announcing that the FDA issued Breakthrough Therapy Designation for its lead candidate setmelanotide as a treatment for hypothalamic obesity. Setmelanotide, marketed as ...
BOSTON, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathw...
-- Rhythm to review data on webcast conference call on November 2, 2022 at 8:30 a.m. ET – -- Rhythm to report 3Q 2022 earnings on November 8, 2022 at 8:00 a.m. ET -- BOSTON, Oct. 25, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-...
-- Approximately 100 European health care professionals invited to discuss recent scientific developments in rare pathway-related obesities -- -- Rhythm presents analysis of Phase 2 Basket Study evaluating setmelanotide in patients with obesity and MC4R variants -- BOSTON, O...
Summary Biotechs are relatively better positioned in this fourth quarter compared to the broader market. Path of interest rates is clearer for 2022 and the Fed is closer to a pause early next year as it calibrates down its response from a hammer approach. Biotechs benefit if a...
Summary Today, we circle back on Rhythm Therapeutics for the first time in over a year and a half. The company continues to advance its main asset Imcivree across multiple indications and recently addressed its near-term financing needs. The stock is up some 125% in 2022 on th...
News, Short Squeeze, Breakout and More Instantly...
Rhythm Pharmaceuticals Inc. Company Name:
RYTM Stock Symbol:
NASDAQ Market:
Rhythm Pharmaceuticals Inc. Website:
BOSTON, July 08, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today announced the appointment of Alastair “Al...
- European Commission decision anticipated in the second half of 2024 - BOSTON, June 28, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rar...
2024-06-14 11:22:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...